Bl. Shulkin et al., NEUROBLASTOMA - POSITRON EMISSION TOMOGRAPHY WITH 2-[FLUORINE-18]-FLUORO-2-DEOXY-D-GLUCOSE COMPARED WITH METAIODOBENZYLGUANIDINE SCINTIGRAPHY, Radiology, 199(3), 1996, pp. 743-750
PURPOSE: To assess the uptake in neuroblastoma of 2-[fluorine-18]-fluo
ro-2-deoxy-D-glucose (FDG) versus metaiodobenzylguanidine (MIBG). MATE
RIALS AND METHODS: Seventeen patients with known or suspected neurobla
stoma underwent FDG positron emission tomography (PET) (20 scans) and
MIBG scintigraphy. Tumor uptake of FDG was quantified on positive FET
scans. RESULTS: Tumor uptake of FDG was detected in 16 of 17 patients
(18 of 20 scans). Neuroblastomas and their metastases avidly concentra
ted FDG prior to chemotherapy or radiation therapy. Uptake after thera
py was variable. Uptake of FDG was intense in one patient with neurobl
astoma that failed to accumulate MIBG. In 13 of the 20 scans, however,
MIBG was rated superior to FDG for delineation of tumor compared with
background and normal organs. CONCLUSION: Most neuroblastomas accumul
ate FDG. The mechanism of MIBG uptake is more intense prior to therapy
. Concentration of FDG is not dependent on type 1 catecholamine uptake
. FDG PET helps define the distribution of neuroblastomas that fail to
concentrate MIBG.